Clinical trial tests customized treatment for ovarian cancer and peritoneal mesothelioma

Ovarian cancer

Ovarian tumor microenvironment
Photo courtesy of NCI Visuals Online

Patients with advanced ovarian cancer or peritoneal mesothelioma may be eligible to participate in a new clinical trial at the NIH Clinical Center.

Christina Annunziata, M.D., Ph.D., of the Women’s Malignancies Branch is leading the Center for Cancer Research’s participation in a study of an experimental, customized therapy for advanced ovarian cancer and peritoneal mesothelioma that have not responded to standard treatments. Ovarian cancer includes cancer of the ovaries, fallopian tubes or abdominal lining (peritoneum). Peritoneal mesothelioma is a type of cancer that affects the peritoneum and is caused by ingesting asbestos fibers. MCY-M11 is a drug derived from the patient’s own white blood cells, which are separated out from the patient’s blood and sent to a manufacturing facility. There, the collected white blood cells (mainly T cells) will be injected with genetic material. This will create a new protein on the T cells that may allow them to target specific kinds of tumor cells. When a sufficient number of genetically altered cells have been produced to make MCY-M11, the customized drug will be sent back to infuse the cells back into the patient’s body. The entire process will take 3 to 4 weeks. The study is designed to find the highest safe dose of MCY-M11.  

Clinicaltrials.gov identifier: NCT03608618
NCI Protocol ID: NCI-18-C-0143
Official Title: A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women With Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects With Peritoneal Mesothelioma With Recurrence After Prior Chemotherapy

The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.  

For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.

Summary Posted: 11/2018